Abstract
repeats by telomerase protects the chromosomes from DNA degradation, end to end fusions, rearrangements and chromosome loss [7] . Inhibition of telomerase activity leads the cells to senescence or death [8] . Although normal somatic cells do not express telomerase, immortalized cells such as tumour cells express this enzyme [9] [10] . The major control mechanism of telomerase activity seems to be the regulation of hTERT expression [11] , because a striking correlation exists between the presence of hTERT mRNA and telomerase activity [12] . In fact, ectopic expression of hTERT in otherwise mortal human cells induced efficient elongation of telomeres and permanent cell growth. [13] . Importantly, telomerase can cooperate with oncogenes or with inactivated tumour suppressor genes to induce tumorigenic conversion of normal human epithelial cells and fibroblasts [14] .
These findings indicate that telomerase plays an important role not only in cellular aging but also in tumorigenesis.
Peroxisome proliferators activated receptor ␥ (PPAR␥) is a member of the nuclear receptor hormone superfamily that was initially shown to be a key regulator of fat cell differentiation [15] [16] . Subsequent studies showed that the antidiabetic drugs, belonging to the thiazolideneidinediones class, bind to the PPAR␥ receptor [17] [18] [19] [20] [21] and two products of oxidative metabolism of linoleic acid, 13-hydroxyoctadecadienoic acid, and 2,4-dienone 13 oxoocta decadienoic acid [22] . Although activation of PPAR␥ will initiate pathways leading to growth arrest, the PPAR␥ ligands seem to act through both a PPAR-dependent and a PPAR-independent mechanism [20] [21] [22] [23] .
and inhibit the growth of a variety of cancer cell types including those of the colon [19-20] Putative endogenous ligands for PPAR␥ include polyunsaturated fatty acids, 15-deoxyprostaglandin J2 (15d-PGJ2)
In colon cancer, PPAR␥ ligands play a controversial role. In fact, agonists of PPAR␥ reduce pre-malignant intestinal lesions in rats treated with the carcinogen azoxymethane [24] but slightly increase colon polyps in Adenomatous polyposis mutant mice that are predisposed to intestinal adenomas [25] Normal colonic mucosa and colonic tumours express abundant PPAR␥ and genetic studies have shown that there are heterozygous loss-of-function mutations in the gene encoding PPAR␥ from tumours in about 10% of human colon cancer patient examined [26] emphasizing that the receptor is likely to have a tumour suppressive function in the colon. In a previous study [27] [28] . C-Myc oncoprotein, through the binding to E-box sequences (CACGTG) in the promoter of hTERT, participates in the control of hTERT expression which was found to limit the rate of telomerase activity [29] . Besides the Myc oncoprotein, the transcriptional repressor Mad1, is able to regulate hTERT promoter-driven reporter gene activity, as it has been demonstrated in transient transfection assays [30] . Moreover, serial deletion assays of the hTERT core promoter revealed that the 5Ј-region containing the E-box, which binds to Myc/Max or Mad1/Max; as well as the 3Ј-region containing five GC-boxes, which binds to Sp1, are essential for transactivation [13] . On Fig. 1. 15d-PG J2 caused a down- (Fig. 1A and B) . The growth of CaCo-2 cells was almost completely blocked for 24 hrs with all the concentrations used (Fig. 1C) Fig. 2A, B) . Cell growth was significantly reduced after treatment with 200 and 250 M rosiglitazone (Fig. 2C) (Fig. 3) . (Fig. 4) . We confirmed the inhibition of c-Myc expression (Fig. 4A) determined by both substances, as previously reported [27] , and observed a strong increase of Mad1 expression at 24 (Fig. 4C) . (Fig. 4D) (Fig. 4F) . Fig. 5 ). (Fig. 6) . The inhibition of hTERT Fig. 1 (A) expression was not reverted by GW9662 in 15d-PG J2-treated cells (Fig. 6A, left side) . On the contrary, GW9662 did partially revert the inhibition of hTERT expression caused by 200 M rosiglitazone (Fig. 6A, right side) . The inhibition of c-myc expression was not reverted by GW9662 in 15d-PG J2 treated cells (Fig. 6B, left side) , whereas it was partially reverted in rosiglitazone-treated cells (Fig. 6B, right side) . Finally, GW9662 did not interfere with the increase of Mad1 protein observed after the treatment with both 15d-PG J2 and rosiglitazone (Fig. 6C, left and  right side, respectively) . 
, we demonstrated that PPAR␥ ligands rosiglitazone and 15d-PG J2 inhibited CaCo-2 colon cancer cell proliferation and reduced the expression of some growth regulatory genes, including c-myc oncogene. The c-myc network proteins (including Myc, Mad and Max proteins) are transcription factors of the basic/helicloop-helix/leucine zipper family that are involved in the control of transcription of several genes

Materials and methods
Cell culture and treatments
Cell proliferation and viability
In 15d-PG J2 -treated cells, the telomerase activity was inhibited by 40%, after 24 hrs and this inhibition became more evident after 48 hrs (65%). Rosiglitazone inhibited telomerase activity by 35% after 24 hrs and by 55% after 48 hrs. With respect to cells treated with rosiglitazone, the inhibition of telomerase activity was stronger in 15d-PG J2-treated cells, which correlates with the degree of inhibition of hTERT expression.
Effects of PPAR␥ ligands on hTERT transcription factor expressions and binding to DNA
To assess whether the inhibition of hTERT expression may be related to the modification of the c-Myc, Mad1 and Sp1 protein content, we analysed these protein expressions 24 and 48 hrs after the treatments
and 48 hrs after treatment with 25 M 15d-PG J2 and only at 48 hrs after treatment with 200 M rosiglitazone (Fig. 4B). Sp1 transcription factor expression did not change after treatments with both 15d PG J2 and rosiglitazone
The DNA binding of c-Myc, Mad1 and Sp1 followed the trend of protein expressions. In fact, Myc binding decreased starting from 24 hrs after both 15d-PG J2 and rosiglitazone treatments
; Mad1 binding strongly increased in 15d-PG J2-treated cells at 24 and 48 hrs, whereas, in rosiglitazone-treated cells, the increase of Mad1 binding was significant only at 48 hrs, and this increase was less pronounced than that observed after 15d-PG J2 treatment (Fig. 4E). Finally, Sp1 binding did not change after both 15d-PG J2 and rosiglitazone treatments
Effects of PPAR␥ ligands in controlling hTERT promoter activity
To determine whether the modulation of Myc and Mad1 expression and binding to DNA could induce modification of hTERT promoter activity, transfection experiments, with two hTERT promoter sequences, containing (Ebox-hTERT-GFP) or not containing (Ebox-less-hTERT-GFP) the E-box binding site, were performed (Fig. 5). The Ebox-hTERT-GFP promoter activity was strongly reduced in cells treated for 48 hrs with 15d-PG J2, whereas the reduction observed in rosiglitazone-treated cells, even if significant, was less pronounced. The Ebox-less-hTERT-GFP promoter activity showed the lowest activity, which was almost absent in 15d-PG J2 and rosiglitazone treated cells. Moreover, we demonstrated that the treatment with both PPAR␥ ligands did not alter the transfection efficiently, measured as expression of GFP under the control of the pCMV (right side of the
Analysis of PPAR-dependence of the effects displayed by PPAR␥ ligands
Because several effects are displayed by PPAR␥ ligands in a PPAR-independent way, we treated CaCo-2 cells with GW9662, a well-known antagonist of PPAR␥
Discussion
In this work we demonstrated that PPAR␥ ligands, 15d-PG J2 and rosiglitazone, inhibit hTERT expression and telomerase activity in colon cancer cells. It has been demonstrated that PPAR␥ ligands can affect telomerase activity and hTERT expression in other cellular models. In fact, rosiglitazone and pioglitazone inhibited telomerase activity in smooth muscle cells [38] , pioglitazone caused a dose-dependent decrease of hTERT mRNA in normal human peripheral blood mononuclear cells [38] [27, 38, 44] , while, on the other, a small number of papers report the modulation of Mad1 expression after drug treatments [46, 47] , although the Mad1 protein was fundamental for hTERT regulation [48] . [51] . In some cases, the PPAR dependence of PPAR␥ ligand effects is related to the dose of ligand employed [52] . Considering the high dose of rosiglitazone used [53] 
